Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 559 of 6351
-
New hope for Hard-to-Treat myeloma: QLS32015 enters phase 3 trial
Disease control Recruiting nowThe purpose of this study is to compare the safety and efficacy of QLS32015 with Pd/Sd for the treatment of relapsed or refractory multiple myeloma.
Phase 3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Real-World data shows promise for CNCT-19 in tough leukemia
Disease control OngoingThis clinical study is a retrospective, observational, and multicenter post marketing real-world study aimed at evaluating the efficacy and safety of CNCT-19 in the treatment of Chinese adult B-cell acute lymphoblastic leukemia patients.
Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New heart mapping technique could improve ablation for persistent AF
Disease control OngoingThe purpose of this study is to establish the safety of the pulsed field ablation (PFA) therapy of Pulmonary Veins and Electrographic Flow (EGF) identified extra-PV sources of atrial fibrillation (PVI + EGF ablation of sources) and to demonstrate its non-inferiority in effectiven…
Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New drug combo aims to wipe out rare blood disease
Disease control Recruiting nowThe purpose of this study is to investigate whether teclistamab-daratumumab combination is effective and safe in AL amyloidosis. The study treatment is divided into cycles (C) and each cycle is 28 days (D). Study treatment is expected to last 6 months.
Phase 2 • Sponsor: Rajshekhar Chakraborty, MD • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Can a Cholesterol-Lowering shot reverse brain artery blockages?
Disease control Recruiting nowThis is a prospective, multicenter, open-label, blinded-endpoint, randomized controlled trial designed to evaluate the efficacy and safety of PCSK9 inhibitor combined with statin therapy compared to statin monotherapy in reversing asymptomatic intracranial atherosclerosis, assess…
Phase 4 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Brain zaps to beat booze: new trial tests magnetic therapy for alcoholism
Disease control Recruiting nowThe study will compare alcohol use in two groups of subjects. One group will be assigned to the Deep TMS treatment and the other group will be assigned to the sham treatment. This is a prospective, 6-month, double blind, randomized, controlled, multi-center trial in outpatients r…
Sponsor: Brainsway • Aim: Disease control
Last updated Sep 10, 2026 08:00 UTC
-
Can we stop these cancer drugs without the tumor coming back?
Disease control Recruiting nowThis phase II trial studies how well de-escalating the drugs dabrafenib and trametinib works in treating patients with low-grade gliomas that have a BRAF V600 gene mutation. Dabrafenib and trametinib are in a class of medications called kinase inhibitors. They work by blocking th…
Phase 2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New combo therapy targets hidden cancer cells in colorectal patients
Disease control Recruiting nowThe researchers are doing this study to find out whether the combination of botensilimab and balstilimab (BOT/BAL), followed by balstilimab alone, is an effective treatment for people with microsatellite stable (MSS) colorectal cancer or colorectal liver metastases (CRLM) who hav…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Can a common steroid save lives after severe burns?
Disease control Recruiting nowBurns affect more than 11 million people worldwide each year. These injuries are responsible for severe morbidity resulting in a high societal burden and account for more than 180,000 yearly deaths especially in low- and middle-income countries. Major burns induce an important l…
Phase 3 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New drug brivekimig aims to tame painful skin abscesses in hidradenitis suppurativa
Disease control Recruiting nowThis is a Phase 2b, global, multicenter, sequential, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study in participants with moderate to severe hidradenitis suppurativa. The purpose of the main study is to assess the efficacy and safety of brivekimi…
Phase 2 • Sponsor: Sanofi • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
One-of-a-Kind drug trial targets rare genetic brain disease
Disease control OngoingThis research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with dentatorubral-pallidoluysian atrophy (DRPLA) due to a heterozygous pathogenic CAG trinucleotide expansion in ATN1
Phase 1/2 • Sponsor: n-Lorem Foundation • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Could a 72-Hour drug course save more lives after cardiac arrest?
Disease control Recruiting nowTo determine if prophylactic administration of amiodarone for 72 hours in critically ill patients admitted after an OHCA with shockable rhythm, with a confirmed or a presumed cardiac cause, decreases the incidence of a composite endpoint of 30-day (starting from inclusion) all-ca…
Phase 3 • Sponsor: Versailles Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Brain tumor breakthrough? shorter radiation shows promise for GBM patients
Disease control Recruiting nowHigh grade gliomas, particularly glioblastoma, are among the most aggressive brain tumors and are associated with poor outcomes despite standard treatment. Many patients, especially older adults or those with poor general health, are not suitable for surgery and have a life expec…
Sponsor: Tata Memorial Centre • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Personalized immune cell therapy takes on lupus and MS
Disease control Recruiting nowAutoimmune diseases occur when the immune system mistakenly attacks the body's own tissues, leading to chronic inflammation and damage to organs such as the kidneys, lungs, muscles, nerves, or blood cells. Although many treatments are available, some patients do not respond adequ…
Phase 1 • Sponsor: Beijing Boren Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Early rhythm control after stroke may save lives
Disease control Recruiting nowThis study will determine whether early, comprehensive, rhythm control therapy prevents adverse cardiovascular outcome in patients with acute ischemic stroke and atrial fibrillation compared to usual care.
Phase 3 • Sponsor: Universitätsklinikum Hamburg-Eppendorf • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Zapping the brain to rebuild memory after injury?
Symptom relief Recruiting nowPatients with working memory deficits due to a moderate to severe head injury will undergo a 5 month protocol including cognitive remediation with numerous exercises, transcranial direct current stimulation (tDCS), and therapeutic education.
Sponsor: University Hospital, Toulouse • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
New shot combo aims to silence hepatitis b virus
Disease control OngoingThis study is A multicenter, randomized, double-blind, placebo-controlled phase 2 clinical study to evaluate the efficacy and safety of HT-101 injection combined with HT-102 injection in patients with chronic hepatitis B. It consists of two phases: the main trial and the extensio…
Phase 2 • Sponsor: Suzhou HepaThera Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Swallow this pill: new capsule could spot internal bleeding instantly
Diagnosis Recruiting nowUpper gastrointestinal bleeding (UGIB) is a common and potentially lethal medical emergency, which requires hospitalization and healthcare resources. Despite the changing epidemiology and advancement of endoscopic therapy in the recent decade, the all-cause mortality of UGIB rema…
Sponsor: Chinese University of Hong Kong • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
New combo aims to melt fat, save muscle in obesity battle
Disease control Recruiting nowIn adults with obesity seeking treatment, weight loss would ideally be composed almost exclusively of fat mass. However, loss of muscle mass and bone are unintentional consequences of weight loss, which may have negative effects on health by lessening improvements in glucose and …
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New hope for liver cancer: drug combo targets tumors after immunotherapy fails
Disease control Recruiting nowWhile immune-based therapies (including targeted-immune or dual-immune regimens) have become first-line standard for advanced hepatocellular carcinoma (HCC), there is a lack of high-level evidence to guide second-line treatment after progression on immune checkpoint inhibitors (I…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC